Table 1.
Baseline characteristics of DTC patients with UM (n = 19).
Table 2.
Clinical characteristics of UM in DTC (n = 19).
Table 3.
Clinical course of UM in DTC patients (n = 19).
Fig 1.
A 34-year-old male patient with follicular variant-papillary thyroid cancer (FV-PTC) showed diffuse lung metastases and unusual metastases to the vastus lateralis muscle in the right thigh.
(A) 131Iodine whole body scan showed radioactive iodine avidity in the anterior neck and metastatic lesions in the neck, both lungs, and right thigh muscles. (B) Ultrasonography showed a round hypoechoic lesion in the muscle of the right thigh. (C) Fine-needle aspiration indicated muscle metastasis from FV-PTC.
Fig 2.
A 71-year-old male patient presenting with pancreatic metastasis from papillary thyroid cancer.
(A, B, C) Endoscopic ultrasonography-guided fine-needle aspiration (FNA) and biopsy showed metastatic PTC on the pancreatic head mass. (A): Hematoxylin and eosin (H-E) staining of FNA (x 400), (B): H-E staining of biopsy (x400), (C): BRAFV600E staining, (D) Abdomen computed tomography (CT) showed 6.9 cm heterogeneously enhancing mass on the pancreatic head before lenvatinib therapy. (E) Follow-up abdomen CT at 3 months after lenvatinib therapy showed the pancreatic tumor decreased in size from 6.9 cm to 4.1 cm. (F) Follow-up abdomen CT at 24 months after lenvatinib therapy showed that the pancreatic tumor was significantly reduced to 1.2 cm.
Table 4.
Treatment response of three TKI-naive patients with pancreatic metastasis treated with lenvatinib.
Fig 3.
Overall survival (OS) in patients with unusual metastases based on Kaplan-Meier curve.